Evans et al.
added with stirring and the flask covered in foil. The flask was
then purged with hydrogen and a hydrogen balloon introduced that
was replaced a further 3 times. After 24 h of stirring at room
temperature the reaction mixture was filtered over Celite washing
with MeOH (300 mL). Removal of the solvent in vacuo afforded
the desired product 24 as an off-white crystalline solid (3.50 g,
15.7 mmol, 99%) that was used without any further purification.
IR (NaCl, Nujol) νmax: 3410-3215, 1725, 1700, 1610, 1521, 1243,
1166, 1059, 850, 810-720 cm-1. 1H NMR (300 MHz, CDCl3): δ
>180 °C dec. IR (NaCl, Nujol) νmax: 3450, 1597, 1561, 1355, 830,
774, 672 cm-1. H NMR (300 MHz, CDCl3): δ 8.73 (br d, J )
1.8 Hz, 1H), 7.92 (m, 2H), 4.98 (s, 2H), 4.74 (s, 2H). 13C NMR
(75.5 MHz, CDCl3): δ 152.9 (C), 142.1 (C), 139.1 (C), 136.7 (C),
135.9 (CH), 131.4 (CH), 125.6 (C), 122.0 (CH), 30.0 (CH2), 20.5
(CH2). MS-ES+ (m/z) 435 ([M + Na]+, 2 × 81Br + 79Br, 74), 433
([M + Na]+, 2 × 79Br + 81Br, 100). HRMS-ES+ (m/z) calcd for
C10H779Br81Br2N2ONa [M + Na]+ 434.7965, found 434.7955.
HRMS-ES+ (m/z) calcd for C10H779Br281BrN2ONa [M + Na]+
432.7986, found 432.7980. Anal. Calcd for C10H7Br3N2O: C, 29.23;
H, 1.72; N, 6.82. Found: C, 29.49; H, 1.43; N, 6.60. The structure
was also confirmed by X-ray crystallographic analysis.5 2,3-Bis-
(bromomethyl)-6-bromoquinoxaline 1,4-dioxide12 was also collected
as a bright yellow crystalline solid (184 mg, 0.43 mmol, 55%).
1
4
3
3
6.92 (br s, 1H), 6.59 (d, J ) 8.2 Hz, 1H), 6.50 (dd, J ) 8.2 Hz,
4J ) 2.3 Hz, 1H), 6.37 (br s, 1H), 3.23 (br s, 4H), 1.49 (s, 9H). 13
C
NMR (75.5 MHz, CDCl3): δ 153.1 (C), 135.7 (C), 131.5 (C), 129.9
(C), 117.2 (CH), 110.5 (CH), 108.0 (CH), 80.0 (C), 28.3 (3 × CH3).
General Procedure for the Preparation of the C6-Substituted
2,3-Bis(bromomethyl)quinoxalines: 2,3-Bis(bromomethyl)-6-
bromoquinoxaline (28). A solution of 1,4-dibromo-2,3-butanedione
(529 mg, 2.17 mmol) in anhydrous THF (20 mL) was added
dropwise to a solution of 2711 (398 mg, 2.13 mmol) in anhydrous
THF (20 mL) at 0 °C over 15 min with stirring. The reaction was
warmed to room temperature and stirred for a further 27 h. After
concentration in vacuo, the crude material was redissolved in DCM
(100 mL) and partitioned between 10% w/v aqueous NaHCO3
solution (200 mL) and DCM (300 mL). The organic phase was
washed with brine (100 mL), dried (MgSO4), filtered, and concen-
trated in vacuo to give a pale brown solid. Purification by flash
column chromatography on silica gel (EtOAc:PE 40-60, 1:9) gave
28 as a white crystalline solid (736 mg, 1.86 mmol, 88%); mp
143.0-144.0 °C. IR (KBr) νmax: 3090, 3027, 2968, 1597, 1476,
General Procedure for Reactions of 2,3-Bis(bromomethyl)-
quinoxalines with Diethylamine. To a solution of the quinoxaline
derivative (0.5 mL of a 40 mM solution in CDCl3) was added a
solution of diethylamine (0.5 mL of a 120 mM solution in CDCl3)
in an NMR tube at 25 °C and the mixture was then monitored by
300 MHz 1H NMR. The excess of diethylamine was used to drive
the reactions to completion, in order to assist interpretation of the
1H NMR spectra.
2,2-Diethyl-2,3-dihydro-1H-pyrrolo[3,4-b]-7-bromoquinoxa-
lin-2-ium Bromide 4-Oxide (35). 35 was prepared according to
the general procedure with 19 and diethylamine. Reaction was
scaled up 6-fold for full analysis. 35 was collected following
crystallization to yield a white crystalline solid (16 mg, 0.04 mmol,
35%); mp >195 °C dec. IR (NaCl, Nujol) νmax: 3458, 1597, 1571,
1368, 1107, 820, 743, 723 cm-1. 1H NMR (300 MHz, DMSO-d6):
1419, 1357, 1211, 939, 833, 799, 722, 638, 603, 569, 426 cm-1
.
4
3
4
1H NMR (300 MHz, CDCl3): δ 8.24 (d, J ) 2.1 Hz, 1H), 7.92
δ 8.49 (d, J ) 2.1 Hz, 1H), 8.42 (d, J ) 9.2 Hz, 1H), 8.06 (dd,
3J ) 9.2 Hz, 4J ) 2.1 Hz, 1H), 5.26 (s, 2H), 5.23 (s, 2H), 3.72 (q,
3J ) 7.1 Hz, 4H), 1.31 (t, 3J ) 7.1 Hz, 6H). 13C NMR (75.5 MHz,
DMSO-d6): δ 153.8 (C), 146.1 (C), 135.5 (C), 133.4 (C), 133.4
(CH) 131.6 (CH), 125.6 (C), 119.7 (CH), 65.4 (CH2), 62.0 (CH2),
57.7 (2 × CH2), 8.4 (2 × CH3); MS-ES+ (m/z) 324 ([M - Br]+,
81Br, 87%), 322 ([M - Br]+, 79Br, 100). HRMS-ES+ (m/z) calcd
for C14H1881BrN3O [M - Br]+ 324.0535, found 324.0538. HRMS-
ES+ (m/z) calcd for C14H1879BrN3O [M - Br]+ 322.0555, found
322.0552.
3
3
4
(d, J ) 8.9 Hz, 1H), 7.85 (dd, J ) 8.9 Hz, J ) 2.1 Hz, 1H),
4.89 (s, 4H). 13C NMR (75 MHz, CDCl3): δ 151.8 (C), 151.1 (C),
142.0 (C), 140.2 (C), 134.4 (CH), 131.3 (CH), 130.2 (CH), 125.1
(C), 30.2 (CH2), 30.1 (CH2); MS-ES+ (m/z) 399 ([M + H]+, 3 ×
81Br, 23%), 397 ([M + H]+, 2 × 81Br + 79Br, 95), 395 ([M + H]+,
2 × 79Br + 81Br, 100), 393 ([M + H]+, 3 × 79Br, 25). Anal. Calcd
for C10H7Br3N2: C, 30.42; H, 1.79; N, 7.09. Found: C, 30.50; H,
1.60; N, 6.94.
General Procedure for the Oxidation of 2,3-Bis(bromometh-
yl)quinoxalines: 2,3-Bis(bromomethyl)-6-bromoquinoxaline 1-Ox-
ide (19). To a solution of 28 (312 g, 0.79 mmol) in anhydrous
DCM (20.0 mL) was added purified mCPBA (1.02 g, 5.93 mmol)
with stirring. After 34 h at room temperature the reaction mixture
was diluted with DCM (20.0 mL) and washed with 10% w/v Na2-
CO3 solution (3 × 20 mL). The organic phase was dried (MgSO4),
filtered, and concentrated in vacuo to give a yellow solid.
Purification by flash column chromatography on silica gel
(EtOAc:PE 40-60, 1:19 to 1:9) gave 19 as a pale yellow solid (37
mg, 0.09 mmol, 18%); mp 144.5-146.0 °C. IR (NaCl, Nujol)
(3-(Diethylaminomethyl)-6-bromoquinoxalin-2-ylmethyl)di-
ethylamine 1-Oxide (36). 36 was recovered from the filtrate in
1
the presence of diethylamine. H NMR (300 MHz, DMSO-d6): δ
3
4
8.36 (d, J ) 9.2 Hz, 1H), 8.32 (d, J ) 2.1 Hz, 1H), 7.94 (dd,
3J ) 9.2 Hz, J ) 2.1 Hz, 1H), 4.24 (s, 2H), 4.06 (s, 2H), 2.63-
4
2.49 (m, 8H), 0.95 (t, 12H). 1H NMR (300 MHz, CDCl3): δ 8.40
(d, 3J ) 9.2 Hz, 1H), 8.23 (d, 4J ) 2.1 Hz, 1H), 7.72 (dd, 3J ) 9.2
4
Hz, J ) 2.1 Hz, 1H), 4.28 (s, 2H), 4.10 (s, 2H), 2.65-2.54 (m,
8H), 1.02-0.97 (m, 12H). 13C NMR (75.5 MHz, CDCl3): δ 158.9
(C), 143.6 (C), 141.7 (C), 134.7 (C), 132.7 (CH), 131.9 (CH), 125.0
(C), 121.0 (CH), 57.6 (CH2), 47.2 (CH2), 47.0 (2 × CH2), 46.5
(2 × CH2), 11.3 (2 × CH3), 11.0 (2 × CH3). MS-ES+ (m/z) 397
([M + H]+, 81Br, 79%), 395 ([M + H]+, 79Br, 100), 379
([M - OH]+, 81Br, 54), 395 ([M - OH]+, 79Br, 55), 324 ([M -
NEt2]+, 81Br, 28), 322 ([M - NEt2]+, 79Br, 32), 308 ([M - O -
NEt2]+, 81Br, 56), 306 ([M - O - NEt2]+, 79Br, 83). HRMS-ES+
(m/z) calcd for C18H2781BrN4ONa [M + Na]+ 419.1245, found
419.1262. HRMS-ES+ (m/z) calcd for C18H2779BrN4ONa [M +
Na]+ 417.1266, found 417.1264.
ν
max: 3450, 1595, 1567, 1351, 1204, 1168, 1107, 1057, 823, 774,
1
4
683, 670 cm-1. H NMR (300 MHz, DMSO-d6): δ 8.40 (d, J )
3
3
4
2.1 Hz, 1H), 8.36 (d, J ) 9.2 Hz, 1H), 8.02 (dd, J ) 9.2 Hz, J
) 2.1 Hz, 1H), 5.00 (s, 2H), 4.99 (s, 2H). H NMR (300 MHz,
1
3
4
CDCl3): δ 8.39 (d, J ) 9.2 Hz, 1H), 8.23 (d, J ) 2.0 Hz, 1H),
7.80 (dd,3J ) 9.2 Hz, 4J ) 2.0 Hz, 1H), 4.96 (s, 2H), 4.73 (s, 2H).
13C NMR (75.5 MHz, CDCl3): δ 153.8 (C), 143.9 (C), 138.8 (C),
135.3 (C), 134.2 (CH), 132.2 (CH), 126.8 (C), 120.7 (CH), 29.9
(CH2), 20.6 (CH2). MS-ES+ (m/z) 435 ([M + Na]+, 2 × 81Br +
79Br, 79), 433 ([M + Na]+, 2 × 79Br + 81Br, 100). HRMS-ES+
(m/z) calcd for C10H779Br81Br2N2ONa [M + Na]+ 434.7965, found
434.7953. HRMS-ES+ (m/z) calcd for C10H779Br281BrN2ONa
[M + Na]+ 432.7986, found 432.7975. The structure was also
confirmed by X-ray crystallographic analysis.5 2,3-Bis(bromo-
methyl)-7-bromoquinoxaline 1-Oxide (20). 20 was also collected
as a white crystalline solid (30 mg, 0.07 mmol, 14%); mp
Acknowledgment. We acknowledge the input of an excel-
lent reviewer who’s suggestion it was to carry out the experi-
ments using limiting concentrations of diethylamine that are
described above and provided strong experimental evidence to
support the computational work. We would like to acknowledge
the assistance of Mrs. M. Smith for NMR, Mrs. C. Horsburgh
(11) Rangarajan, M.; Kim, J. S.; Sim, S-P.; Liu, A.; Liu, L. F.; La Voie,
E. J. Bioorg. Med. Chem. 2000, 8, 2591-2600.
(12) Musatova, I. S.; Elina, A. S.; Solov’eva, N. P.; Polukhina, L. M.;
Moskalenko, N. Y.; Pershin, G. N. Pharm. Chem. J. 1983, 17, 779-784.
3192 J. Org. Chem., Vol. 72, No. 9, 2007